Invasive cutaneous fungal infections requiring radical resection in cancer patients undergoing chemotherapy

Journal of Surgical Oncology
Ravi RadhakrishnanHenry M Kuerer

Abstract

Invasive fungal infections have emerged as a significant problem in patients with cancer with the development of better systemic therapies for malignancy and more effective antibacterial agents. The currently available world published medical literature was reviewed on invasive fungal infections in cancer patients with specific attention devoted to the multidisciplinary role of surgery in refractory cutaneous cases. Infections can develop on the forearm where peripheral intravenous catheters had been inserted in cancer patients undergoing cytotoxic chemotherapy. Curative intent begins with systemic contemporary anti-fungal therapy. Following resolution of neutropenia, patients may require radical surgical debridement with negative margins of resection for complete eradication of the fungal infection. Although invasive fungal infections refractory to antifungal systemic therapy in immunocompromised patients undergoing chemotherapy are a rare event, it is critical for surgeons and other multidisciplinary clinicians to recognize these potentially life-threatening infections that may necessitate radical surgical resection for cure.

References

Sep 28, 1979·JAMA : the Journal of the American Medical Association·M HenriquezJ L Rosenbaum
Mar 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A M Sugar
Oct 29, 1987·The New England Journal of Medicine·M D AlloC Tan
Jul 1, 1997·Clinical Microbiology Reviews·O Lortholary, B Dupont
Nov 20, 1998·The Journal of Infection·A ChakrabartiV K Sakhuja
Jan 25, 2002·The New England Journal of Medicine·Thomas J WalshUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group
Jan 25, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David W DenningHartmut Lode
Feb 28, 2002·Expert Opinion on Investigational Drugs·Holly L Hoffman, R Chris Rathbun
Aug 9, 2002·The New England Journal of Medicine·Raoul HerbrechtUNKNOWN Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillu
Oct 26, 2002·Journal of the American Academy of Dermatology·Gerald P BodeyIssam Raad

❮ Previous
Next ❯

Citations

Jun 16, 2009·Bone Marrow Transplantation·M Aguilar-GuisadoJ M Cisneros
Dec 19, 2006·Seminars in Cutaneous Medicine and Surgery·Steven R Mays, Philip R Cohen
Mar 10, 2006·Plastic and Reconstructive Surgery·Ali Al-AttarRichard J Redett
Nov 2, 2019·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Victor G Prieto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.